BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL)

Uncategorized·equity

$1.10

-0.90% today

Prices delayed about 15 minutes · cached page, can be an hour old or more

Market Census Score

56/ 100

Score level

Above average

4 of 6 checks had data

Score for how it compares with the broader market is above the middle.

BCTXL scores higher than 78% of the 11,953 tickers we compare it with (all tickers we score).

As of 9 October 2026, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) scores 56 out of 100 on the Market Census six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.

Updated 9 October 2026 · scores usually change about once a day

Key statistics

Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.

This listing is not a company’s common stock — it may be a note, preferred share, warrant, right, unit or an exchange test symbol. Company-wide figures such as market cap, earnings and dividends belong to an issuer, not to this listing, so they are not shown here.

Relative volume: 3.01× 30-day average
52-week range: —
Market cap: —
Earnings date: —

Volume: 36,915
Avg. volume (30d): 12,276

Open: 1.09
Previous close: 1.11
Day's range (regular session): 1.09 – 1.10

The last trade can be an extended-hours trade, so it can sit outside the regular-session range.

Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.

Beta: —
P/E (TTM): —
EPS (TTM): —

Score breakdown · six named factors

Price trend

Strength vs the market

Company finances

—

Insider trades

—

Market mood

Recent momentum

Each bar is one part of the score, from 0 to 100. Read what the score means.

What the score says about BCTXL right now

BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) currently scores 56/100 on the Market Census six-factor composite, at the Above average score level. BCTXL is -0.90% on the day and -3.93% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for BCTXL leans good, with some weak spots. BCTXL's strongest factor is strength vs the market at 75/100 — a strong read on how BCTXL has done next to the wider market. It describes what has happened, not what happens next. The weakest factor is market mood at 50/100 — middling backdrop. A weak market mood drags every name in the cohort; if BCTXL is still scoring well on the composite despite this, the company-specific factors must be doing heavy lifting.

Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.

See BCTXL in the scanner

This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).

Create your account →Share on X Embed this score

Recent BCTXL news

Latest headlines that name BriaCell Therapeutics Corp. Warrant expiring 2031, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).